US Pharma MarketingThe setback dims the outlook for a medicine Pfizer sees as an important contributor going forward, though some analysts are optimistic about the drug’s chances in another trial.
Pfizer drug acquired in Seagen deal disappoints in lung cancer study
The setback dims the outlook for a medicine Pfizer sees as an important contributor going forward, though some analysts are optimistic about the drug’s chances in another trial.
Source: BioPharma Dive